Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Apo-Pindol (00755877), Apo-Pindol (00755885), Apo-Pindol (00755893). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

PINDOLOL

5 general benefit · 1 not a benefit

Other products in the same Health Canada class (C07A) — coverage varies; not interchangeable

  • Labetalol (Trandate): general benefit

Teva-Pindolol · DIN 00869007 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Pindolol · DIN 00869007 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Daily cost (source): $0.8136 Health Canada: Marketed since 2011-10-20 · brand TEVA-PINDOLOL · ATC C07AA03 PINDOLOL · form Tablet · route Oral · ingredients PINDOLOL 5 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Pindolol: Formulary list price $0.4068/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4068 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10949 · Verify on the e-Formulary ↗ (DIN 00869007)

Source record
DIN 00869007: Teva-Pindolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240800058; group id 345; item number 0784; lccId None; manufacturer id TEV Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4068; ministry $0.4068 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00869007 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10949
Interchangeable products
Visken · DIN 00417270 · $0.4068
Shortage status: discontinued (2016-12-05, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00869007
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Pindolol · DIN 00869015 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Pindolol · DIN 00869015 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Daily cost (source): $1.3894 Health Canada: Marketed since 2011-10-20 · brand TEVA-PINDOLOL · ATC C07AA03 PINDOLOL · form Tablet · route Oral · ingredients PINDOLOL 10 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Pindolol: Formulary list price $0.6947/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6947 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10950 · Verify on the e-Formulary ↗ (DIN 00869015)

Source record
DIN 00869015: Teva-Pindolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240800057; group id 345; item number 0785; lccId None; manufacturer id TEV Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.6947; ministry $0.6947 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00869015 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10950
Interchangeable products
Visken · DIN 00443174 · $0.6947
Shortage status: discontinued (2015-06-05, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00869015
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Pindolol · DIN 00869023 · 15mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Pindolol · DIN 00869023 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Daily cost (source): $1.9566 Health Canada: Marketed since 2011-10-20 · brand TEVA-PINDOLOL · ATC C07AA03 PINDOLOL · form Tablet · route Oral · ingredients PINDOLOL 15 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Pindolol: Formulary list price $0.9783/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9783 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10951 · Verify on the e-Formulary ↗ (DIN 00869023)

Source record
DIN 00869023: Teva-Pindolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240800056; group id 345; item number 0786; lccId None; manufacturer id TEV Source form: Tab; strength: 15mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.9783; ministry $0.9783 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00869023 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10951
Interchangeable products
Visken · DIN 00417289 · not recorded
Shortage status: resolved shortage (ended 2023-07-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00869023
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Visken · DIN 00417270 · 5mg · tablet

General benefitDormant since 2026-01-07 · checked 2026-09-02 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Visken · DIN 00417270 Manufacturer: Aralez Pharmaceuticals Canada Inc.; listing date 1996-10-01 Daily cost (source): $1.7344 Health Canada: Dormant since 2026-01-07 · brand VISKEN · ATC C07AA03 PINDOLOL · form Tablet · route Oral · ingredients PINDOLOL 5 MG · company Xediton pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.4068 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3089 · Verify on the e-Formulary ↗ (DIN 00417270)

Source record
DIN 00417270: Visken Raw flags: chronicUseMed=Y, sec3=Y Item: 240800058; group id 345; item number 0784; lccId None; manufacturer id ARZ Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.8672; ministry $0.4068 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00417270 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3089
Interchangeable products
Teva-Pindolol · DIN 00869007 · $0.4068
Shortage status: active shortage (reported 2025-05-01, last updated 2025-10-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00417270
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-01-07 — choose a marketed DIN from the same-category list.

Visken · DIN 00443174 · 10mg · tablet

General benefitDormant since 2026-01-07 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Visken · DIN 00443174 Manufacturer: Aralez Pharmaceuticals Canada Inc.; listing date 1996-10-01 Daily cost (source): $2.9614 Health Canada: Dormant since 2026-01-07 · brand VISKEN · ATC C07AA03 PINDOLOL · form Tablet · route Oral · ingredients PINDOLOL 10 MG · company Xediton pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.6947 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3091 · Verify on the e-Formulary ↗ (DIN 00443174)

Source record
DIN 00443174: Visken Raw flags: chronicUseMed=Y, sec3=Y Item: 240800057; group id 345; item number 0785; lccId None; manufacturer id ARZ Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.4807; ministry $0.6947 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00443174 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3091
Interchangeable products
Teva-Pindolol · DIN 00869015 · $0.6947
Shortage status: active shortage (reported 2025-05-01, last updated 2025-10-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00443174
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-01-07 — choose a marketed DIN from the same-category list.

Visken · DIN 00417289 · 15mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-07-13 — choose a marketed DIN from the same-category list.Discontinued 2017-07-13 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-07-13 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-07-13 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Visken · DIN 00417289 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Daily cost (source): $1.9566 Health Canada: Cancelled post market since 2017-07-13 · brand VISKEN · ATC C07AA03 PINDOLOL · form Tablet · route Oral · ingredients PINDOLOL 15 MG · company Tribute pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Visken: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3090 · Verify on the e-Formulary ↗ (DIN 00417289)

Source record
DIN 00417289: Visken Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240800056; group id 345; item number 0786; lccId None; manufacturer id NOV Source form: Tab; strength: 15mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00417289 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3090
Interchangeable products
Teva-Pindolol · DIN 00869023 · $0.9783
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00417289
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2017-07-13 — choose a marketed DIN from the same-category list.

PINDOLOL & HYDROCHLOROTHIAZIDE

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (C07A) — coverage varies; not interchangeable

  • Labetalol (Trandate): general benefit

Viskazide · DIN 00568627 · 10mg & 25mg · tablet

General benefitDormant since 2025-09-20 · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Viskazide · DIN 00568627 Manufacturer: Aralez Pharmaceuticals Canada Inc.; listing date 1996-10-01 Health Canada: Dormant since 2025-09-20 · brand VISKAZIDE · ATC C07CA03 PINDOLOL AND OTHER DIURETICS, C07CA03 PINDOLOL AND OTHER DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, PINDOLOL 10 MG · company Xediton pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Viskazide: Formulary list price $1.3666/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3666 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5156 · Verify on the e-Formulary ↗ (DIN 00568627)

Source record
DIN 00568627: Viskazide Raw flags: chronicUseMed=Y, sec3=Y Item: 240800086; group id 346; item number 0787; lccId None; manufacturer id ARZ Source form: Tab; strength: 10mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.3666; ministry $1.3666 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00568627 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5156
Shortage status: active shortage (reported 2025-05-01, last updated 2025-10-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00568627
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-09-20 — choose a marketed DIN from the same-category list.

Viskazide · DIN 00568635 · 10mg & 50mg · tablet

General benefitDormant since 2025-09-30 · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Viskazide · DIN 00568635 Manufacturer: Aralez Pharmaceuticals Canada Inc.; listing date 1996-10-01 Health Canada: Dormant since 2025-09-30 · brand VISKAZIDE · ATC C07CA03 PINDOLOL AND OTHER DIURETICS, C07CA03 PINDOLOL AND OTHER DIURETICS · form Tablet · route Oral · ingredients PINDOLOL 10 MG, HYDROCHLOROTHIAZIDE 50 MG · company Xediton pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Viskazide: Formulary list price $1.3666/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3666 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5157 · Verify on the e-Formulary ↗ (DIN 00568635)

Source record
DIN 00568635: Viskazide Raw flags: chronicUseMed=Y, sec3=Y Item: 240800085; group id 346; item number 0788; lccId None; manufacturer id ARZ Source form: Tab; strength: 10mg & 50mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.3666; ministry $1.3666 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00568635 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5157
Shortage status: active shortage (reported 2025-05-01, last updated 2025-10-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00568635
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-09-30 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

LABETALOL HCL

· 6 products · General benefit · strengths: 100mg, 200mg · Tab

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab

CILAZAPRIL & HYDROCHLOROTHIAZIDE

· 2 products · General benefit · strengths: 5mg/12.5mg · Tab

CLONIDINE HCL

· 17 products · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) · strengths: 0.025mg, 0.1mg, 0.2mg · Tab

DOXAZOSIN MESYLATE

· 12 products · Listed, not a benefit (3), General benefit (9) · strengths: 1mg, 2mg, 4mg · Tab

ENALAPRIL MALEATE

· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

FELODIPINE

· 12 products · General benefit (10), Listed, not a benefit (2) · strengths: 2.5mg, 5mg, 10mg · ER Tab, SR Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08 and 34 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE ACEBUTOLOL HCL · Listed, not a benefit (3), General benefit (6) INDICATIONS AND CLINICAL USE APO-ACEBUTOLOL is indicated for the following:  Treatment of mild to moderate hypertension.  Long-term management of patients with angina pectoris due to ischemic heart disease. PM: https://pdf.hres.ca/dpd_pm/00047998.PDF; date October 24, 2018; DIN 02147602; fetched 2026-09-10 Product monograph AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) 1 INDICATIONS NORVASC (amlodipine besylate tablets) is indicated for: • Hypertension NORVASC is indicated in the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10 Product monograph AZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit 1 Part 1: Healthcare Professional Information Indications • EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10 Product monograph BENAZEPRIL · Listed, not a benefit (3), General benefit (3) Indications BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:  Treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL · General benefit • Heart Failure o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in addition to standard therapy, with or without an ACE inhibitor. 1.1 Pediatrics Pediatrics (6 to 17 years of age): • Hypertension ATACAND is indicated for the treatment of essential hypertension in children and adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS). PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph • Hypertension PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS ATACAND PLUS (candesartan cilexetil/hydrochlorothiazide) is indicated for: • the treatment of essential hypertension in patients for whom combination therapy is appropriate. PM: https://pdf.hres.ca/dpd_pm/00076288.PDF; date JUN 18, 2001; DIN 02244021; fetched 2026-09-10 Product monograph CHLORTHALIDONE · Listed, not a benefit (1), General benefit (2) 1 INDICATIONS APO-CHLORTHALIDONE (chlorthalidone) is indicated for: • Treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10 Product monograph CILAZAPRIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:  treatment of mild to moderate essential hypertension in patients for whom combination therapy with both cilazapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00066994.PDF; date September 07, 1995; DIN 02181479; fetched 2026-09-10 Product monograph CLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) INDICATIONS AND CLINICAL USE TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10 Product monograph ENALAPRIL MALEATE & HYDROCHLOROTHIAZIDE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS VASERETIC® (enalapril and hydrochlorothiazide) is indicated for:  Treatment of essential hypertension in patients for whom this combination therapy with enalapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00068096.PDF; date November 4, 2022; DIN 00657298; fetched 2026-09-10 Product monograph and 20 more Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS Hypertension TEVA-PINDOLOL (pindolol) is indicated for the treatment of mild to moderate hypertension. Pindolol is usually used in combination with other drugs, particularly a thiazide diuretic. However, it may be used alone as an initial agent in those patients in whom, in the judgment of the physician, treatment should be started with a β-blocker rather than a diuretic. The combination of pindolol with a diuretic and/or peripheral vasodilator has been found to be compatible and generally more effective than pindolol alone. Limited experience with other antihypertensive agents, including methyldopa, has not shown evidence of incompatibility with pindolol. TEVA-PINDOLOL is not recommended for the emergency treatment of hypertensive crises. Angina Pectoris TEVA-PINDOLOL is indicated for the prophylaxis (prevention) of angina pectoris. https://pdf.hres.ca/dpd_pm/00050790.PDF PM date: April 23, 2019 Source product: TEVA-PINDOLOL; DIN 00869007; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Availability

Teva-Pindolol · DIN 00869007 Shortage status: discontinued (2016-12-05, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00869007

Check this DIN again

Teva-Pindolol · DIN 00869015 Shortage status: discontinued (2015-06-05, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00869015

Check this DIN again

Visken · DIN 00417270 Shortage status: active shortage (reported 2025-05-01, last updated 2025-10-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00417270

Check this DIN again

Visken · DIN 00443174 Shortage status: active shortage (reported 2025-05-01, last updated 2025-10-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00443174

Check this DIN again

Viskazide · DIN 00568627 Shortage status: active shortage (reported 2025-05-01, last updated 2025-10-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00568627

Check this DIN again

Viskazide · DIN 00568635 Shortage status: active shortage (reported 2025-05-01, last updated 2025-10-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00568635

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Visken: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026